EoPancreas: New Diabetes Patch Pump and CGM System in Development

$ 12.50

4.6
(417)
In stock
Description

FDA has granted "Breakthrough Device Designation" to South Korean company EoFlow, developing a tubeless patch-pump based Automated Insulin Delivery (AID) system.
FDA has granted Breakthrough Device Designation to South Korean company EoFlow, developing a tubeless patch-pump based Automated Insulin Delivery (AID) system.

What's New In Diabetes Technology in 2023?

December update on closed-loop systems

Diabetes Café (@Diabetesto) / X

Medtronic drops $738m takeover of wearable insulin pump firm

Diabetes Device Development

Diabeloop to offer EOPatch system in Europe - Desang Diabetes Services

Comparison of Automated Insulin Delivery Systems

Medtronic buys EOFlow for its wearable insulin patch technology

NEWS EOFLOW

The Future of Closed-Loop Systems

EoPancreas: New Diabetes Patch Pump and CGM System in Development

Medtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor - Jan 8, 2024

Artificial Pancreas aka Automated Insulin Delivery: What You Should

Omnipod CGM and Pump Patch - Diabetes UK Shop

Artificial Pancreas - NIDDK